Hologic, Inc. $HOLX Shares Purchased by Oak Thistle LLC

Oak Thistle LLC lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 182.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,629 shares of the medical equipment provider’s stock after purchasing an additional 40,444 shares during the period. Hologic comprises about 0.6% of Oak Thistle LLC’s portfolio, making the stock its 6th biggest holding. Oak Thistle LLC’s holdings in Hologic were worth $4,665,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company increased its holdings in Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after acquiring an additional 8,227,318 shares in the last quarter. Bank of America Corp DE lifted its position in Hologic by 2.2% in the second quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock valued at $201,364,000 after buying an additional 66,453 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Hologic by 5.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,917,418 shares of the medical equipment provider’s stock valued at $196,897,000 after buying an additional 149,605 shares during the last quarter. Nordea Investment Management AB lifted its position in Hologic by 9.5% in the third quarter. Nordea Investment Management AB now owns 2,832,600 shares of the medical equipment provider’s stock valued at $190,067,000 after buying an additional 245,186 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Hologic by 25.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,141,736 shares of the medical equipment provider’s stock worth $143,582,000 after purchasing an additional 439,916 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of research reports. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Finally, Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and reduced their price objective for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Two research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus price target of $78.42.

Hologic Trading Up 0.5%

NASDAQ:HOLX opened at $76.01 on Wednesday. The company has a market capitalization of $16.97 billion, a PE ratio of 31.67, a price-to-earnings-growth ratio of 2.24 and a beta of 0.70. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $76.07. The stock has a fifty day simple moving average of $75.31 and a 200-day simple moving average of $73.83.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the firm earned $0.87 EPS. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic News Summary

Here are the key news stories impacting Hologic this week:

• Positive Sentiment: Blackstone and TPG completed the $17 billion take‑private acquisition of Hologic at $79.00 per share, so public shareholders receive the deal consideration and the company will be delisted. Hologic (HOLX) Goes Private
• Positive Sentiment: Official press release confirming close and leadership transition — private equity owners named Joe Almeida as CEO to lead Hologic under Blackstone/TPG ownership. This clarifies post‑deal management and reduces execution uncertainty. Blackstone and TPG Complete Acquisition
• Neutral Sentiment: Company announcement/confirmations of the takeover and leadership changes echoed across outlets (filings/PR). These are procedural confirmations of the already‑announced deal. Hologic Taken Private in Blackstone-TPG Acquisition
• Neutral Sentiment: Trading in HOLX was halted earlier for “news pending,” consistent with exchange protocol around a material deal close. That halt resolved with the deal confirmation. (No link — market notice)
• Negative Sentiment: Hologic will be removed from the S&P 500; Casey’s General Stores is being added to the index to replace HOLX. Removal from the index means ETFs and passive funds tracking the S&P will sell the shares — a temporary negative for short‑term liquidity, though offset by the cash‑out at $79. Casey’s General Stores (CASY) Shares Jump
• Negative Sentiment: Unusual options activity ahead of the close showed a surge in put purchases, indicating elevated hedging or bearish positioning prior to the announcement; such activity can signal uncertainty but is largely moot now that the deal closed. S&P 500 change coverage

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.